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INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia and is 
related with cardiovascular disorders, including heart failure 
and stroke, and doubles the associated mortality rate.1 Several 
studies have indicated diastolic dysfunction to be an indepen-
dent predictor of AF.2 The presence and severity of diastolic 
dysfunction might be associated with the left atrium (LA) sub-
strate of AF and progressive atrial mechanical remodeling due 
to increased LA pressure.3 Increased left ventricular (LV) fill-
ing pressure has been linked with all-cause mortality, an in-
creased frequency of LA appendage thrombus, and stroke in 
non-valvular AF patients.4
We hypothesized that the AF recurrence is associated with 
the degree of diastolic dysfunction in patients with persistent 
AF after cardioversion. Several studies have demonstrated 
that increased LV filling pressure may affect AF recurrence af-
ter cardioversion.2,4 Therefore, this study set out to determine 
whether increased LV filling pressure is associated with an in-
creased risk of AF recurrence after cardioversion in patients 
with persistent AF. In contrast to previous studies, to limit the 
effect of LA structural remodeling which is in the pathogene-
sis of AF, we enrolled patients without extreme LA enlarge-
ment. A limited number of studies have investigated how dia-
stolic parameters may predict AF recurrence after cardioversion 
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by using echocardiography. Here, we investigated the predic-
tors of AF recurrence in patients undergoing continued anti-
arrhythmic drug therapy after cardioversion.
MATERIALS AND METHODS
Study population
The study retrospectively enrolled 66 patients (57 males, mean 
58±12 years) with newly diagnosed non-valvular, lone, and 
persistent AF from January 2009 to December 2012 at the 
Gangnam Severance Hospital, Yonsei University College of 
Medicine. Persistent AF was defined as continuous AF sus-
tained greater than 7 days, according to the expert consensus 
statement.5 For patients with newly diagnosed AF, heart rate 
was controlled below 110 beats/minute and maintained by 
using beta blockers or calcium channel blockers. After heart 
rate control, pre-treatment with flecainide for 2 weeks was 
performed in all patients before electrical cardioversion. 
Those patients who were converted to sinus rhythm by pre-
treatment with flecainide were labeled as the chemical car-
dioversion group. Electrical cardioversion was performed in 
the remaining patients who were not converted to sinus 
rhythm by flecainide treatment. These patients were labeled 
as the electrical cardioversion group. All 66 patients were con-
verted to sinus rhythm by either flecainide treatment or elec-
trical cardioversion. After cardioversion, flecainide was ad-
ministered continuously in order to maintain sinus rhythm. 
All patients who underwent electrical cardioversion had taken 
oral anticoagulation with vitamin K antagonists such as war-
farin for 4 weeks and had maintained optimal prothrombin 
time (PT) international normalized ratio (INR) range of 2.0 to 
3.0 before the cardioversion. Exclusion criteria were: 1) LV 
ejection fraction (EF) <50%, 2) LA anterior-posterior (AP) di-
mension >50 mm, and 3) known coronary artery disease 
(CAD) or suspected CAD. The patients were divided into two 
groups according to AF recurrence: group 1, with AF recurrence 
(n=40); and group 2, without AF recurrence (n=26). Electronic 
medical records were reviewed, and pertinent data points were 
recorded. All patients provided written, informed consent.
Echocardiographic study
After rate control, two-dimensional transthoracic echocar-
diography (TTE) was performed. All the echocardiographic 
studies were performed using an iE33 (Philips Ultrasound, 
Bothell, WA, USA) with an S3 probe. Comprehensive echo-
Doppler and M-mode evaluation were assessed in all patients 
before cardioversion. Left ventricle wall thicknesses was mea-
sured during end-diastole phases. LA AP dimension was mea-
sured at end-systole from the parasternal long axis view. All 
measurements were done according to current American So-
ciety of Echocardiography guidelines.6 The modified Simp-
son’s rule was used to calculate LV volumes and EF from api-
cal 2- and 4-chamber views. The prolate ellipse method was 
used to calculate LA volume from apical 4-chamber and para-
sternal long-axis views at ventricular end-systole, then LA vol-
umes were indexed to body surface area. 
Peak early (E) and late (A) diastolic mitral inflow velocities 
were measured in apical 4-chamber view. Tissue Doppler in-
terrogation was done in septal mitral annulus in apical 4-cham-
ber view, and then peak systolic mitral annulus velocity and 
early diastolic mitral annulus peak velocity (e’) were measured, 
and the ratio of E/e’ was calculated. Pulsed Doppler and 
pulsed tissue Doppler parameters were measured as the aver-
age of three cardiac cycles, and the R-R intervals were relatively 
regular except during lasting atrial fibrillation. 
Follow-up
After the diagnosis of AF, patients were treated by flecainide 
for two weeks. If sinus rhythm was not achieved after chemi-
cal cardioversion, electrical cardioversion was performed. All 
patients were scheduled for regular follow-up visits after car-
dioversion, including clinical examination, and 12-lead elec-
trocardiography (ECG) every 3 months and Holter monitoring 
every 6 months. In the case of symptom recurrence between 
follow-up visits, patients were evaluated by additional clinical 
examination, ECG, and Holter monitoring. AF recurrence af-
ter cardioversion was defined as any documented supraven-
tricular tachyarrhythmia, such as AF, atrial flutter, or atrial 
tachycardia episode, lasting >30 seconds. 
Statistical analysis
Continuous variables that are normally distributed are report-
ed as mean±SD or 95% confidence interval (CI). Student t-test 
was used to compare the means of continuous variables that 
were approximately normally distributed between the two 
groups. Continuous variables that were not normally distrib-
uted are reported as median (25–75 percentile range) and are 
compared using the Kruskal-Wallis test. Normality was deter-
mined using the Kolmogorov-Smirnov goodness-of-fit test. 
Categorical variables are reported as count (percentage) and 
are compared using Fisher’s exact test. 
Independent predictors of AF recurrence after cardiover-
sion were assessed using univariate Cox proportional hazards 
regression models, and multivariable models were assessed 
based on the results of univariate models. Multivariate analy-
sis (stepwise forward and enter method) was done with vari-
able with p<0.05 in univariate analysis. Differences in cumu-
lative event-free survival rate between patients with and 
without elevated LV filling pressure were explored using the 
Kaplan-Meier method followed by log-rank test. Receiver op-
erating characteristic (ROC) analysis was performed to evalu-
ate the values for predicting AF recurrence and identify the 
optimal cut-off values for E/e’ level. A p-value of ≤0.05 was 
considered statistically significant. 
The SPSS statistical package (IBM, Markham, Canada) was 
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used to perform all statistical evaluations. 
 
RESULTS
Patient characteristics
The baseline characteristics of the patients are presented in 
Table 1. There were no differences in the age, gender, hyper-
tension, diabetes, dyslipidemia, stroke, smoking and CHA2DS2-
Vasc score between the groups. There were no differences in 
the LA AP dimension, LV mass index, or LV EF between the 
groups. Group 1 had an increased LA volume index (LAVI; 
30.30±8.32 mL/m2 vs. 25.47±7.75 mL/m2, p=0.021) and E/e’ 
(10.9±3.7 vs. 8.3±2.3, p=0.002) compared with group 2. The 
difference of E/e’ between two groups is described with rep-
resentative cases in Fig. 1, and depicted by scatter plots in Fig. 
2. There were no significant difference in the prescribed med-
ications such as beta blocker, calcium channel blocker, angio-
tensin-converting enzyme inhibitor and angiotensin II recep-
tor blocker. 
Diastolic function and recurrence rate of AF after 
cardioversion 
The conversion to sinus rhythm during pre-treatment with 
flecainide was achieved in 39/66 patients (59.1%). Electrical 
cardioversion was carried out in the remaining patients, 27/66 
(40.9%). All patients were converted to sinus rhythm with ei-
ther chemical or electrical cardioversion. During a mean fol-
low-up period of 25±19 months, the recurrence rate of AF af-
ter cardioversion was 60.61% (40/66; 48.7% vs. 77.8% in 
chemical cardioversion vs. electrical cardioversion). The 
chemical cardioversion group had a decreased LA volume in-
dex (47.66 mL/m2 vs. 65.44 mL/m2, p<0.001) compared to the 
electrical cardioversion group. There was no difference in the 
value of E/e’ (9.7±3.3 vs. 10.6±4.1, p=0.351) between these two 
groups.
The area under the ROC curve of E/e’ for AF recurrence was 
0.780 (95% CI: 0.657–0.903). ROC analysis showed the optimal 
cut-off value for the E/e’ for predicting AF recurrence level to 
be 9.15 with 75.0% of sensitivity and 73.1% of specificity (Fig. 3). 
Univariate Cox proportional hazards regression analysis 
showed that LAVI [hazards ratio (HR): 1.045, 95% CI: 1.007–
1.085, p=0.020], LV mass index (HR: 1.022, 95% CI: 1.001–
1.042, p=0.036) and the ratio of E/e’ (HR: 1.113, 95% CI: 1.031–
1.202, p=0.006) were significant predictors of AF recurrence 
after cardioversion. Multivariate Cox proportional hazards re-
gression analysis with stepwise forward method revealed that 
E/e’ (HR: 1.100, 95% CI: 1.017–1.190, p=0.017) and LAVI (HR: 
Table 1. Baseline Characteristics 
Group 1 (n=40) Group 2 (n=26) p value
Age, yrs 58±13 58±11 0.988
Male, n (%) 35 (86.4) 22 (85.0) 1.000
Underlying diseases, n (%)
Hypertension 20 (48.8) 14 (56.0) 0.619
Diabetes 9 (22.0) 3 (12.0) 0.512
Stroke 6 (14.6) 1 (4.0) 0.239
Dyslipidemia 8 (19.5) 2 (8.0) 0.297
Medication, n (%)
BB 9 (22.5) 3 (11.5) 0.126
CCB 32 (80.0) 22 (84.6) 0.252
ACEi 2 (5.0) 3 (11.5) 0.243
ARB 17 (42.5) 8 (30.8) 0.108
Aspirin 22 (55.0) 17 (65.4) 0.176
Warfarin 16 (40.0) 9 (34.0) 0.168
CHADS2 score 1.1±1.3 0.7±0.7 0.080
CHA2DS2-Vasc score 1.6±1.5 1.3±1.1 0.379
LA diameter, mm 39.63±5.43 37.69±5.37 0.161
LA volume index, mL/m2 30.30±8.32 25.47±7.75 0.021
LV mass index, g/m2 91.56±17.19 84.98±15.97 0.123
LV EF, % 65±7 66±9 0.780
E, cm/s 0.80±0.26 0.70±0.19 0.110
e’, cm/s 0.08±0.03 0.09±0.03 0.325
E/e’ 10.9±3.7 8.3±2.3 0.002
DT, ms 219±72 192±48 0.370
LA, left atrium; LV, left ventricle; EF, ejection fraction; E/e’, the ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (e’); DT, de-
celeration time; BB, beta blocker; CCB, calcium channel blocker; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin ll receptor blocker.
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1.042, 95% CI: 1.002–1.084, p=0.042) were independent pre-
dictors for AF recurrence after cardioversion (Table 2 and 3). 
Fig. 4 shows the Kaplan-Meier survival curves for AF recur-
rence with or without elevated LV filling pressure. The cumu-
lative recurrence-free survival rate was significantly lower in 
patients with elevated LV filling pressure (E/e’>9.15) than pa-
tients without elevated LV filling pressure (E/e’≤9.15) (log 
rank p=0.008).
DISCUSSION
This study investigated the relationship between LV filling 
pressure and AF recurrence after cardioversion. In line with 
previous reports, overall AF recurrence rate in our study pop-
ulation was 60.6% (40/66).7,8 Diastolic dysfunction is linked 
with poorer cardiovascular outcomes, development of AF, 
more severe AF symptoms, as well known.9 The main finding 
of this study was that elevated LV filling pressure, as indicated 
by the increased E/e’ ratio, was correlated significantly with 
AF recurrence after cardioversion. Our present study enrolled 
only patients who were newly diagnosed with AF in the ab-
sence of extremely enlarged LA. In this way, we were able to 
more effectively isolate the effect of LV filling pressure on AF 
A
B
Fig. 1. The representative cases which reveal the difference of E/e’ between two groups. (A) In patients without recurrence, early (E) diastolic mitral in-
flow peak velocity and early diastolic mitral annulus peak velocity (e’) were measured, and the ratio of E/e’ was calculated. (B) In patients with recur-
rence, the ratio of E/e’ was calculated by the same way.
Fig. 2. The scatter plots of E/e’ with or without AF recurrence. AF, atrial fi-
brillation; E/e’, the ratio of mitral peak velocity of early filling (E) to early di-
astolic mitral annular velocity (e’).
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recurrence. The results suggested that elevated LV filling pres-
sure may predict the outcome after cardioversion in patients 
with persistent AF. 
Evaluation of diastolic function in AF patients and 
echocardiographic parameters
Evaluation of diastolic function involves integration of multi-
ple echocardiographic parameters. Diastolic dysfunction is 
characterized by a progressive decrease in LV compliance 
with corresponding impairment in myocardial relaxation, re-
sulting in elevated LV end diastolic pressure despite normal 
end diastolic volume.2 Clinically useful parameters, which re-
flect the pressure gradient between the LA and LV, include 
mitral inflow Doppler patterns of early filling peak velocity (E), 
atrial peak velocity (A), the E/A ratio, and deceleration time 
(DT). These transmitral flow parameters are affected by load-
ing status, and DT varies as it is dependent on the cardiac cy-
cle length. Therefore, they need to be considered in combina-
tion with tissue Doppler imaging, which is less dependent on 
preload. Since, atrial systolic waves (A wave, atrial peak veloc-
ity) are lost in AF patients, it is difficult to evaluate diastolic 
function based on transmitral flow velocity. 
Mitral annular velocity (e’), determined by pulsed wave tis-
sue Doppler, is a relatively preload-independent variable, and 
has been demonstrated to be an excellent marker of LV relax-
ation.10 Therefore, E/e’ reflects the LV filling pressure and is 
useful for evaluating diastolic function. Indeed, several stud-
ies have reported that E/e’ is associated with LV filling pres-
sure, even in AF patients, with sensitivities >70% and specifici-
ties >90%.11 Furthermore, Okura, et al.9 reported that E/e’ was 
a strong predictor for heart failure in AF patients. In our study, 
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Fig. 3. Receiver operating characteristic (ROC) curves for E/e’ for AF re-
currence after cardioversion. Area under the ROC curve for E/e’ was 
0.780 (95% confidence interval: 0.657–0.903, p<0.001). AF, atrial fibrillation; 
E/e’, the ratio of mitral peak velocity of early filling (E) to early diastolic mi-
tral annular velocity (e’).
Table 2. Univariate Cox Proportional Hazards Regression Analysis for Predicting AF Recurrence after Cardioversion
Variables HR 95% CI p value
Age, per 1 yr increase 1.003 0.975–1.031 0.851
Male gender 0.847 0.546–1.313 0.457
Hypertension 0.925 0.489–1.750 0.811
Diabetes mellitus 0.820 0.376–1.791 0.619
Dyslipidemia 1.176 0.490–2.821 0.717
CHADS2 score 1.088 0.838–1.411 0.527
CHA2DS2-VASc score 1.004 0.803–1.257 0.969
LV EF, per 1% increase 0.985 0.949–1.023 0.440
LA diameter, per 1 mm increase 1.033 0.971–1.098 0.305
LA volume index, per 1 mm3/m2 1.045 1.007–1.085 0.020
LV mass index, per 1 g/m2 increase 1.022 1.001–1.042 0.036
E/e’, per 1 increase 1.113 1.031–1.202 0.006
AF, atrial fibrillation; HR, hazards ratios; CI, confidence interval; LV, left ventricle; EF, ejection fraction; LA, left atrium; E/e’, the ratio of mitral peak velocity of ear-
ly filling (E) to early diastolic mitral annular velocity (e’).
Table 3. Multivariate Cox Proportional Hazards Regression Analysis for Predicting AF Recurrence after Cardioversion
Variables
Stepwise forward method Enter method
HR 95% CI p value HR 95% CI p value
LA volume index, per 1 mm3/m2 1.042 1.002–1.084 0.042 1.040 1.000–1.082 0.050
E/e’, per 1 increase 1.100 1.017–1.190 0.017 1.079 0.992–1.174 0.076
LV mass index, per 1 g/m2 increase 1.013 0.991–1.036 0.256
AF, atrial fibrillation; HR, hazards ratios; CI, confidence interval; LA, left atrium; LV, left ventricle; E/e’, the ratio of mitral peak velocity of early filling (E) to early 
diastolic mitral annular velocity (e’).
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the ratio of E/e’ was a significant independent predictor of AF 
recurrence after cardioversion, indicating that LV filling pres-
sure may be associated with AF recurrence. Since estimating 
E/e’ during AF is less accurate than the same measure taken 
during sinus rhythm, we measured these parameters while 
the R-R intervals were relatively regular after rate control. 
Recurrence of AF after cardioversion according to LV 
filling pressure
The association between the recurrence of AF after cardiover-
sion and echocardiographic parameters reflecting diastolic 
dysfunction remains inadequately assessed. In the present 
study, we found that LV filling pressure was significantly cor-
related with AF recurrence after cardioversion. 
When LV compliance is reduced, pressure essentially backs 
up, causing an increase in LA pressure. This atrial pressure 
overload leads to atrial electrical and structural remodeling 
including atrial stretching, dilatation and fibrosis. These 
changes provide a vulnerable substrate for AF.12 The mecha-
nism of AF initiation and recurrence in patients with diastolic 
dysfunction stems from this progressive remodeling.3,13 Long-
term volume overload could be predicted by both the LAVI 
and E/e’, while long-term pressure overload of the LA leads to 
progressive LA enlargement and electrical instability, which 
reflect the severity of diastolic dysfunction. Therefore, AF re-
currence after cardioversion is associated with elevated LV 
filling pressure and LA remodeling. Some studies have dem-
onstrated LAVI to be an independent predictor of AF recur-
rence.14 The duration of AF reflects the degree of atrial remod-
eling and has also been demonstrated to be an important 
predictor of the success of cardioversion.14 
Some studies have demonstrated that diastolic dysfunction 
might predict AF recurrence after cardioversion therapies.2,4 
The LA structural remodeling reflects the chronicity of expo-
sure to abnormal filling pressures as consequence of diastolic 
dysfunction.14 Caputo, et al.4 identified an enlarged LA vol-
ume and an elevated E/e’ as predictors of AF recurrence after 
electrical cardioversion. However, they enrolled AF patients 
with no regard to LA size. This resulted in their study popula-
tion to include patients with extremely enlarged atria. It is 
highly likely that elevated LV filling pressure, resulted from di-
astolic dysfunction, might cause the intrinsic pathologic 
physiologic change of LA before LA enlargement. LA dysfunc-
tion had been observed before LA enlargement in patients 
with paroxysmal AF, and this might be due to the reduction of 
booster pump function of LA, such as intrinsic active relax-
ation and contractility rather than conduit function.15,16 Our 
study enrolled only patients who were newly diagnosed with 
AF in the absence of extremely enlarged LA. In these patients, 
the atria have not been given ample time to structurally re-
model, thus resulting in an unchanged LA size. 
Importantly, several studies have reported an LA diameter 
above 50 mm predicts the AF recurrence.17 By design, our 
study excluded patients with LA diameters larger than 50 mm 
in order to avoid the associated effects on AF recurrence. In 
this way, we could more effectively isolate the effect of LV fill-
ing pressure on AF recurrence, and found that E/e’ was an in-
dependent predictor for AF recurrence after cardioversion, 
and an elevated E/e’ was associated with poorer outcomes af-
ter cardioversion in patients with persistent AF patients. 
Therefore, we conclude that LV filling pressure, estimated by 
E/e’, is predictive of AF recurrence after cardioversion even in 
the absence of extreme atrial enlargement. 
Clinical implication
It is important to manage diastolic dysfunction with optimal 
medical therapy. We can possibly do more intensive observa-
tion of symptoms and volume status of the patients with high-
er E/e’ and without extreme LA enlargemt, and more aggres-
sive medical treatment. The elevated LV filling pressure could 
be an early sign of left atrial pathological process before LA re-
modeling, presented as LA enlargement. Based on the result 
of this study, we carefully suggest that early medical interven-
tion could improve the clinical prognosis regarding AF recur-
rences before the extreme LA enlargement observed by TTE. 
Proper management can attenuate the structural and electri-
cal remodeling of the atria, typically associated with diastolic 
dysfunction, thereby limiting AF recurrence after cardiover-
sion. Therefore, medical therapy targeted at reducing LV fill-
ing pressure is important before and after cardioversion. Re-
nin-angiotensin system (RAS) inhibitors, such as angiotensin-
converting enzyme inhibitor or angiotensin ll receptor blocker 
might reduce LV filling pressure. These medications may at-
tenuate structural remodeling and electrical remodeling, and 
subsequently the recurrence of AF, by promoting the regres-
sion of atrial fibrosis.18 Indeed, Fukuda, et al.19 demonstrated 
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Fig. 4. The Kaplan-Meier survival curves for AF recurrence in patients af-
ter cardioversion with or without increased LV filling pressure. AF, atrial 
fibrillation; E/e’, the ratio of mitral peak velocity of early filling (E) to early 
diastolic mitral annular velocity (e’); LV, left ventricle. 
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that E/e’ was higher in non-RAS inhibitor medication group 
than RAS inhibitor medication group. Although two prospec-
tive studies reported that RAS blockers could not suppress AF 
recurrence,20,21 Ishikawa, et al.22 demonstrated that RAS inhib-
itor significantly reduced the AF recurrence after pulmonary 
vein isolation. Generally, therefore, these previous studies 
support that these drugs might reduce AF recurrence by de-
creasing LV filing pressure, the primary risk factor for AF re-
currence assessed in this study. Based on the present results, 
further assessment of LV filling pressure as a valuable predic-
tor of clinical outcomes associated with AF recurrence may 
help evaluate the effectiveness of these drugs. Moreover, a 
prospective study is needed to evaluate whether medical 
therapies aimed at lowering LV filling pressure could reduce 
AF recurrence after cardioversion and improve clinical out-
comes in AF patients. 
Limitations
The present study has several limitations. This study was per-
formed at a tertiary referral hospital, and there might be some 
selection and referral bias. The relatively small number of en-
rolled patients in this study is also a limitation. Additional 
echocardiographic parameters, such as left atrial appendage 
velocities using transesophageal echocardiography, were not 
considered in this study. Until now, there is no established 
method for evaluating LV diastolic function in AF patients, al-
though several studies have reported clinical usefulness of E/
e’ to estimate LV filling pressure in this population.9 Therefore, 
we could not identify an association between diastolic dys-
function and AF recurrence. Additionally, Doppler parame-
ters measured during AF could be less accurate than in the si-
nus rhythm, although we minimized this complication by 
measuring these parameters while the R-R intervals were rela-
tively regular. Our study indicated that the echocardiographic 
parameters, indicating diastolic function such as E/e’ ratio, 
can be reasonably assessed in AF patients. We think that more 
prospective studies are needed to firmly confirm the relation-
ship between the medical treatment of diastolic dysfunction 
and the improvement of clinical prognosis regarding AF re-
currences.
Conclusions
Our study provides data that support the assessment of LV fill-
ing pressure to predict clinical outcomes after cardioversion. 
The presence of LV diastolic dysfunction is a crucial mediator 
of AF development and recurrence. After cardioversion, pa-
tients with an elevated LV filling pressure, estimated by the E/
e’ ratio, had an increased AF recurrence rate without extreme 
LA enlargement. These results suggest that elevated LV filling 
pressure might predict the outcome after cardioversion of AF 
regardless of the degree of mechanical atrial remodeling. 
Therefore, it is important to manage diastolic dysfunction, in-
cluding reduction of LV filling pressure, in order to reduce the 
AF recurrence rate and improve the outcome in patients with 
persistent AF after cardioversion. For early detected AF pa-
tients without extreme LA enlargement, reduction of LV filling 
pressure after cardioversion might decrease the risk of AF re-
currence. 
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